Furthermore, high-dose G-CSF (30 μg/kg/day) mobilized CD123+ DC in patients with multiple myeloma but only occasionally in those affected by non-Hodgkin's lymphoma, and exerted varying effects on CD11c+ DC [43]. This evidence concerns the gene ITGAX and non-Hodgkin lymphoma.